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Johann P Ingimarsson1,4*, Martin I Sigurdsson1, Sverrir Hardarson2, Vigdis Petursdottir2, Eirikur Jonsson1,
Gudmundur V Einarsson1 and Tomas Gudbjartsson1,3Abstract
Background: The observed low metastatic potential and favorable survival of small incidentally detected renal cell
carcinomas (RCCs) have been a part of the rationale for recommending partial nephrectomy as a first treatment
option and active surveillance in selected patients. We examined the relationship between tumor size and the odds
of synchronous metastases (SMs) (primary outcome) and disease specific survival (secondary outcome) in a
nationwide RCC registry.
Methods: Retrospective study of the 794 RCC patients diagnosed in Iceland between 1971 and 2005. Histological
material and TNM staging were reviewed centrally. The presence of SM and survival were recorded. Cubic spline
analysis was used to assess relationship between tumor size and probability of SM. Univariate and multivariate
statistics were used to estimate prognostic factors for SM and survival.
Results: The probability of SM increased in a non-linear fashion with increasing tumor size (11, 25, 35, and 50%) for
patients with tumors of ≤4, 4.1-7.0, 7.1-10.0, and >10 cm, respectively. On multivariate analysis, tumor size was an
independent prognostic factor for disease-specific survival (HR = 1.05, 95% CI 1.02-1.09, p < 0.001), but not for SM.
Conclusion: Tumor size affected the probability of disease-specific mortality but not SM, after correcting for TNM
staging in multivariate analysis. This confirms the prognostic ability of the 2010 TNM staging system for renal cell
cancer in the Icelandic population.
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The ability to detect subclinical small renal cell carcin-
omas (RCCs) has greatly improved due to increased usage
of abdominal imaging for unrelated disease [1]. This has
altered the therapeutic approach to RCCs and over the
past decade, nephron-sparing surgery (NSS) has replaced
radical nephrectomy as the preffered treatment for RCCs
less than 7 cm in size, when technically feasible, as sug-
gested by both the European and American Guidelines
[2,3]. These guidelines further recommend active surveil-
lance or other minimally invasive treatments (i.e. radioa-
blation or cryotherapy) as an alternative to surgery for* Correspondence: johann.p.ingimarsson@hitchcock.org
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article, unless otherwise stated.patients with significant co-morbidities or advanced age.
This is in part based on the assumption that the biological
behaviour of smaller tumours is more benign than that of
larger tumours, after observations of a low rate of metastasis
and better survival of patients with smaller tumours [2-4].
The importance of knowing the exact size in predic-
tion of outcome has been a matter of debate in the lit-
erature. While the study by Klatte et al., which focussed
on tumours smaller than 4 cm, did not find a significant
relationship between tumor size and the probability of
SM and survival, numerous other studies have supported
such a correlation [5-11]. Several studies have evaluated
various size cut-off points to improve prognostication, but
there have been conflicting results [12]. The 2010 revision
of the TNM system emphasized size by subdividing the T2
stage into T2a and T2b catergories at the 10-cm cut-offntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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any prognostic difference between the two new stages
[13,14].
Most studies that have investigated the relationship
between size and SM have been based on data from single
or multiple institutions. Importantly two population-based
databases are available: the Surveillance, Epidemiology, and
End-Results Database (SEER) and the National Swedish
Kidney Cancer Quality Register (NSKCR) [6,7,15,16]. While
covering larger populations, these databases did not offer a
central review of staging or pathology, risking inter obser-
ver discrepancies with regards to stage and histology.
We therefore conducted a nationwide study using a
centralized RCC database and a revised histological
classification to test the relationship between RCC size
and the probability of SM (primary outcome) and DSS
(secondary outcome).
Methods
We conducted a retrospective nationwide study that in-
cluded all patients diagnosed with RCC in Iceland between
January 1, 1971 and December 31, 2005. The Icelandic
Cancer Registry and centralized pathology and clinical
registries of all hospitals in Iceland were cross-checked
with the inclusion list, giving a 100% match.
Clinical information was obtained from the medical
records, including age, gender, symptoms, diagnostic
work-up, and treatment. An incidental diagnosis was de-
fined as tumours detected with imaging techniques or
during surgery for reasons other than those related to
clinical signs caused by renal tumours. In surgical cases,
routine lymphadenectomy was not performed, but en-
larged lymph nodes were usually removed. Postoperative
follow-up was performed at each hospital or at out-
patient clinics for the first 1–2 years. Follow-up there-
after for recurrence was per physician preference and
not standardized. A chest X-ray was performed in all
patients preoperatively, together with a computed tom-
ography (CT) and/or ultrasound (US) of the liver when
these tests became available. CT scans of the chest,
brain, bone scans, magnetic resonance imaging (MRI),
or cavography were performed selectively. PET scan was
not available in Iceland during the study period.
Two of the authors, both consulting pathologists (S.H.
and V.P), reviewed haematoxylin and eosin-stained slides,
using accepted criteria by WHO and the Heidelberg clas-
sification for stratifying the histological subtypes [17]. The
following pathology findings were recorded: Fuhrman nu-
clear four-grade scale, lymph node status, invasion of ves-
sels, adrenals, and Gerotas fascia. As imaging modalities
varied during the study period, tumour size was deter-
mined from the pathology specimens as the greatest
diameter in mm. In the non-surgically treated cases,
size, as measured by radiologists from CT scans, US, orintravenous pyelograms, was used. The spread of tu-
mours was assessed using the most recent version of
the TNM classification system and with stage grouping
(I–IV) as proposed by AJCC [17,18]. Synchronous me-
tastases were defined as metastases present at or within
three months of the diagnosis of the primary kidney
tumour.
All the patients were followed up for survival by using
data from the updated National Population Registry, and
they were assigned a date and cause of death (as regis-
tered on the death certificate) or identified as living
on 31 December 2009. Median follow-up of survival was
4.5 years (range 0–34 years), and none of the patients
were lost to follow-up.
Chi-square test and Mann–Whitney U test were used to
compare univariate proportions and means, respectively.
A p-value of < 0.05 was considered to be statistically sig-
nificant. To graphically demonstrate a relationship be-
tween tumour size and probability of SM, we used cubic
spline analysis—which makes no assumption about the re-
lationship between parameters and is entirely data-driven.
Independent prognostic factors for the presence of SM
were assessed with logistic regression. The model included
all univariate variables with p < 0.1. This included age,
gender, calender year of diagnosis, tumor size, incidental
diagnosis, histological subtype, laterality, estimated sedi-
mentation rate (ESR) and pT stage. Since pT stage is
highly dependant on size, analysis for SM were performed
both with and without pT stage.
Cox proportional hazards analysis was used to deter-
mine independend predictors of and disease-specific sur-
vival (DSS). Cox proportional hazards analysis was used
to determine independend predictors of disease-specific
survival (DSS), using data from all patients with suffi-
cient histology and staging data (n = 794). The model in-
cluded all univariate variables with a p-value of < 0.1,
including size, group TNM-stage and Fuhrman grade,
ESR levels, incidental diagnosis, and calendar year of diag-
nosis. In the multivariate analysis for SMs, the pT stage ra-
ther than the TNM group stage was used, since the
presence of metastases was included in the TNM group
subset. Size was considered a continuous variable in all
multivariate analysis.The statistical software package R,
version 2.10.1, was used for all analyses (the R Foundation,
Vienna, Austria).
This study was approved by the National Bioethics
Committee and the Icelandic Data Protection Agency.
As individual patients were not identified, individual
consent for the study was waived.
Results
Altogether, 913 patients were diagnosed with RCC during
the 35 year study period, but 116 patients were excluded;
65 because detailed information on tumor size was lacking
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(histology missing). This left 794 with histopathologically
confirmed disease that were used for calculations. Nephrec-
tomy was performed in 702 out of 794 cases (4.1% of them
partial) with 92 patients being treated non-surgically. No
patients were treated with cryothearpy or radioablation, as
these techniques were only available after 2006 in Iceland.
Patient demographics and treatment are shown in
Table 1. The ratio of males to females was 1.5, the average
age was 65 years, and 29% of the tumors were detected
incidentally.Size and synchronous metastases
Mean tumor size was 7.2 ± 3.8 cm (median 6.7, range 0.3–
30.0). Tumors diagnosed in the first 5 years were larger
(8.4 cm) than those diagnosed in the last 5 years (6.5 cm)
(p < 0.01 for trend). The proportion of patients with con-
firmed pT stages 1, 2, 3, and 4 were 35%, 17%, 39%, and
4%, respectively. Altogether, 247 patients (30%) were diag-
nosed with SMs, with lungs (n = 121), bones (n = 80), and
liver (n = 51) being the most common metastatic sites.
When pathologically confirmed tumors were classified
into 1-cm size categories, there was a positive correl-
ation between increasing size and the probability of SM
(Figure 1) (R2 = 0.80, p < 0.0001). This correlation was
retained in a sub analysis of localized tumors (pT1 and
pT2) (R2 = 0.83, p < 0.0001), but not when the pT3 or
pT4 tumors were analyzed (R2 = 0.58, p = 0.12). Figure 2
shows a cubic spline analysis of the relationship between
size and the probability of SM.
Table 2 shows a comparison of patients with and with-
out SM. Patients with SM had significantly larger tumors
(mean 9.0 vs. 6.5 cm) (p < 0.001), higher T stage, higher
Fuhrman grade, higher ESR, and earlier calendar year of
diagnosis. Furthermore, they were less frequently diag-
nosed incidentally and more often had tumor in the left
kidney. There were, however, no significant differences
in gender, age, or histological subtype. The proportion of
SM for tumours less than 4.0 cm was 11% (20/188), but
7% when only tumors detected after 1990 were included
(90% of them being diagnosed incidentally).Table 1 Patient characteristics
Average age (range) 64.0 ± 12.9 (17–93)
Male: female ratio 1.6
Right kidney, n (%) 413 (59)
Incidental detection, n (%) 150 (21)
First treatment
Radical nephrectomy, n (%) 673 (84)
Partial nephrectomy, n (%) 29 (4)
Non surgical on no treatment, n (%) 92 (12)A multivariate logistic regression analysis revealed that
symptomatic diagnosis, elevated ESR, left kidney tumor
and a size increment of 1 cm were independent prognos-
tic factors for SM (Table 3). In a model including tumor
stages, size was not retained as an independent prognostic
factor. However, symptomatic presentation, elevated ESR
and left kidney tumor continued to be independent prog-
nostic factors. When included, higher tumour stage was
the strongest predictor in all models.
Size and survival
There was significantly better survival in patients with
smaller tumors (p < 0.001, log rank test). DSS at 5 years
was 86% for tumors of < 4 cm, 72% for tumors between
4 and 7 cm, 53% for tumors between 7 and 11 cm, and
32% for tumors larger than 11 cm.
In a univariate analysis, less favorable DSS was related
to the following factors: increasing tumor size, higher
group stage and Fuhrman grade, high ESR levels, pre-
sentation with symptoms, and year of diagnosis. In the
Cox analysis shown in Table 4, TNM group stage,
Fuhrman nuclear grade, calendar year of diagnosis, and
incidental detection were still independent predictors of
DSS. Size remained a statistically significant albeit small
predictor (HR = 1.05, CI 1.02–1.09, p <0.001) when TNM
group stage was added to the multivariate model.
A subcategory of patients with histopathologically
confirmed and organ confined (T1/T2,N0,M0) RCC
(without synchronous metastasis) underwent nephrec-
tomy (n = 370); 6% of them with partial nephrectomy.
Sixty four of the 370 patients (17.4%) ultimately died
from RCC, 5–371 (mean 100, medial 70) months after
surgery. Patient characteristics and univariate analysis
are shown in Table 5. A multivariate logistic regression
analysis revealed that only year of diagnosis (OR 0.93
for each calendar year), elevated ESR (OR 1.01 per
1 mm/hour) and a size (OR 1.21 per one cm increment,
95% CI 1.03-1.58, p = 0.02) were independent prognostic
factors for DSS in this subcategory of patients. If the
multivariate model also included tumor stage, size fell
short of being retained as an independent prognostic
factor (OR 1.17, 95% CI 0.99-1.39, p = 0.053).
Discussion
Our results show that increasing size of RCC tumours
is associated with a higher probability of SM and worse
survival in an unselected nationwide RCC registry.
Tumour size remained an independant predictive fac-
tor for DSS after multiple corrections, albeit with
a limited additional prognostic value when the TNM
group stage was added to the model. While tumor size
did predict SM in multivariate analysis, it did not inde-
pendently predict the probability of SM when the T
stage was added to the model.
Figure 1 Proportion of synchronous metastases as stratified by 1-cm tumor size intervals. Tumors above 16 cm (n = 18) have been
pooled, as there were less than 2 cases in each 1-cm category.
Ingimarsson et al. BMC Urology 2014, 14:72 Page 4 of 7
http://www.biomedcentral.com/1471-2490/14/72Our results add to the findings from studies using the
SEER and the NSKCR databases, which were also popula-
tion based patient cohorts [6,7,15]. The strength of our
study is that the data include all patients diagnosed in a
whole country over a 35-year period. This eliminates the
risk of inclusion bias or referral bias. Other strengths are
the centrally reviewed histology and complete follow-up
with regard to survival. We intentionally excluded clinic-
ally diagnosed RCCs without histopathologic confirmationFigure 2 A cubic spline graph showing the relationship between tum
patients dignosed in Iceland, 1971–2005. Dotted lines show 95% CI.as these cases may have included benign kidney tumors
and thus falsely improved the survival. It could also be ar-
gued that by excluding the clinically diagnosed cases, the
RCC patients with the worst prognosis may have been
omitted. However, including the clinically diagnosed pa-
tients from the multivariate analysis did not significantly
change our main findings, neither for SM-rate or survival.
A weakness of the study is the retrospective design, rela-
tively small number of patients, with differences in theour size and the probability of synchronous metastases in RCC
Table 2 Comparison of clinicopathological factors for RCC
patients diagnosed with and without synchronous
metastases (SMs) in Iceland, 1971–2005
N SM (%)
Without
SM (%) p-value*
Mean age 794 65 (±13) 65 (±13) 0.87
Gender
Male 481 137 (29) 344 (71) 0.81
Female 313 87 (28) 226 (72)
Year of diagnosis < 0.001
1971–1975 65 23 (35) 45 (65)
1976–1980 65 22 (36) 41 (64)
1981–1985 92 36 (39) 56 (61)
1986–1990 103 40 (38) 64 (62)
1991–1995 127 32 (25) 95 (75)
1996–2000 139 25 (18) 114 (82)
2001–2005 202 44 (22) 158 (78)
Diagnosis < 0.001
Incidental 236 14 (6) 222 (94)
Symptomatic 558 207 (37) 351 (63)
Laterality** < 0.001
Right kidney 427 94 (22) 333 (78)
Left kidney 359 122 (34) 237 (66)
Mean ESR 29.7 (±32) 59.1 (±39) < 0.001
Tumor size by category < 0.001
0.1–4.0 177 19 (11) 158 (89)
4.1–7.0 252 64 (25) 188 (75)
7.1–10.0 226 80 (35) 146 (65)
10.1–13.0 76 35 (46) 41 (54)
13.1–16.0 46 24 (53) 22 (47)
> 16.0 17 10 (61) 7 (39)
T stage < 0.001
T1a 154 6 (4) 148 (94)
T1b 140 12 (9) 128 (91)
T2a 92 16 (17) 76 (82)
T2b 51 14 (36) 37 (64)
T3 328 125 (38) 203 (62)
T4 30 11 (63) 19 (47)
Histological RCC subtype 0.13
Clear cell 705 194 (28) 511 (72)
Papillary 65 14 (22) 41 (78)
Chromophobe 15 1 (7) 14 (93)
Other 9 3 (33) 5 (66)
Nuclear grade < 0.001
I - II 449 66 (15) 383 (85)
III - IV 345 147 (43) 198 (57)
*Mann–Whitney test for means, Chi-square test for trends.
**Excluding 8 bilateral cases.Number of patients is given with percentage in
parentheses, except for ESR and age where mean is given together with
standard deviation.
Table 3 Multivariate analysis of the importance of size
for the rate of synchronous metastases in patients
diagnosed with RCC in Iceland, 1971–2005
Odds ratio 95% CI p
Tumor size (per cm) 1.09 1.04-1.16 0.001
Age 1.00 0.98-1.01 0.9
Female gender 0.87 0.57-1.30 0.49
Later diagnostic year (per decade) 1.02 0.91-1.13 0.94
Incidental diagnosis 0.22 0.11-0.41 <0.001
ESR (each 1 mm/h) 1.15 1.09-1.21 <0.001
Left side 1.67 1.12-2.50 0.013
Histology
Clear cell 1 - -
Chromophobe 1.37 0-infinity 0.98
Papillary 0.93 0.42-2.03 0.81
Other/unknown 1.27 0.11-14.71 0.5
ESR and Size are continuous varibles.
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over time, as well as changes in treatment options being
offered. Further, in our study, average size is larger and in-
cidental diagnosis less frequent than obtained in more
contemporary series and may not reflect the more recent
increase in incidentalomas.
The correlation between size and the probability of
SM was strong in our data (Figures 1 and 2). Our findings
are in line with the study by Kunkle et al. where tumour
size independently predicted the odds of SM [9]. More re-
cently, an almost linear relationship between size and SM
for tumours ≤ 7 cm was described by Gudmundsson et al.
in the NSKCR study [7]. In addition, based on the SEER
database, Lugezzani et al. reported a similar relationship
for T1 tumours, and Nguyen et al., found a sigmoidal rela-
tionship between size and SM that was comparable to the
findings in the present study [6,15].
The proportion of SM in the present study was higher
than reported in other clinical studies, most of them
contemporary series, with SM rates ranging between
0.1% and 7% [10,19-21]. In population databases, the re-
ported proportion of SM from the SEER database ranged
from 3% to 6% and in the NSKCR study it was 7%
[6,7,15]. This is similar to the SM-rate (7%) found in our
patients diagnosed after 1990. Unlike NSKCR, we did
not evaluate the relationship between size, SM, and
lymph node involvement, as lymph nodes were not sys-
tematically sampled or removed.
For tumors between 4.0 and 7.0 cm, we found the rela-
tionship between size and SM rate to be virtually linear.
This is in line with most previous studies [6,9,15]. For
tumours larger than 7.0 cm, earlier reports have shown
that further increase in size adds less to metastatic po-
tential [6,15]. While the shape of our cubic spline might
Table 4 Multivariate analysis of the predictors for disease
specific survival in patients diagnosed with RCC in
Iceland, 1971–2005
Hazard ratio 95% CI p-value
Tumor size (cm) 1.05 1.02–1.09 0.01
Later diagnostic year (by decades) 0.90 0.85-0.95 0.01
Incidental detection 0.74 0.52–1.03 0.08
Left sided tumour 1.14 0.91-1.41 0.24
TNM group stage
1 1 - -
2 2.34 1.36-3.99 <0.001
3 3.54 2.21-5.71 <0.001
4 13.16 8.14-21.28 <0.001
Fuhrman nuclear grade
1 1 - -
2 0.79 0.41-1.54 0.49
3 1.10 0.56-2.13 0.78
4 1.74 0.86-3.49 0.12
Histology
Clear cell 1 - -
Chromophobe 0.13 0.01-0.97 0.046
Papillary 0.88 0.52-1.46 0.61
Other/unknown 1.61 0.39–6.64 0.51
Table 5 Comparison of clinicopathological factors of
patients with organ confined RCC without synchronous
metastases who underwent nephrectomy by cause
of death
N Death from
RCC (%)
Did not die
from RCC (%)
p-value*
Mean age 370 62 (±13) 62 (±12) 0.62
Gender
Male 227 41 (18) 186 (82) 0.67
Female 143 23 (16) 120 (84)
Year of diagnosis < 0.001
1971–1975 26 8 (31) 18 (79)
1976–1980 27 9 (33) 18 (67)
1981–1985 45 10 (22) 35 (88)
1986–1990 36 10 (28) 26 (82)
1991–1995 59 12 (20) 47 (75)
1996–2000 79 9 (11) 72 (89)
2001–2005 96 6 (8) 90 (92)
Diagnosis < 0.001
Incidental 165 18 (11) 147 (89)
Symptomatic 205 46 (22) 159 (78)
Laterality** 0.004
Right kidney 205 28 (14) 177 (86)
Left kidney 165 36 (22) 129 (78)
Mean ESR (mm/h) 21.0 (±24) 38.8 (±40) < 0.001
T stage < 0.001
T1a 144 7 (5) 137 (95)
T1b 124 22 (18) 102 (82)
T2a 76 24 (32) 52 (68)
T2b 26 11 (42) 15 (58)
Tumor size (cm) 5.1 (±2.9) 7.6 (±3.1) < 0.001
Histological RCC
subtype
0.21
Clear cell 315 56 (18) 256 (82)
Papillary 42 8 (19) 34 (81)
Chromophobe 11 0 (0) 11 (100)
Other 2 0 (0) 2 (0)
Nuclear grade < 0.001
I - II 299 40 (14) 259 (85)
III - IV 71 24 (34) 47 (66)
Number of patients is given with percentage in parentheses, except for ESR
and age where mean with standard deviation is given.
*Mann-Whitney test for means, Chi-square for trends.
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widens with increasing size, making it difficult to sup-
port such statements.
Despite the seemingly strong relationship between size
and SM, it is noteworthy that the association is not sta-
tistically retained in a multivariate analysis after correct-
ing for pT stage, grade, incidental detection, laterality,
and other factors that were significant in the univariate
analysis. At the same time, size clearly correlated with
DSS in the Cox multivariate analysis. It has previously
been shown in multivariate analyses not including stage,
that size is a significant predictor of DSS, disease-free
survival, and SM, with HR and OR of 1.2 or less [22,23].
Karakiewitz et al. included TNM stage in the multi-
variate analysis of 2,245 patients and found that knowing
the exact size added 3.7% to the predictive accuracy
for SM and only 0.8% to the predictive accuracy for
DSS (2002 version) [24]. This, as well as the strong pre-
dictive value of of pT stage for SM and TNM stage for
DSS in the present study, appears to confirm the value
of the most recent (7th) version of the TNM-staging
system.
Conclusion
We have shown in a nationwide cohort that tumour
size correlates strongly with the rate of SM and is anindependent prognostic factor of long-term survival after
correcting for confounding variables. Tumor size there-
fore aids in prognostication, and is an addition to that
predicted by the TNM-staging system, however, the dif-
ference is small.
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